Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting

Cancer

Volumn 97, Issue 9, 2003, Pages 2290-2300

  Chawla, Sant P ^a   Grunberg, Steven M ^b   Gralla, Richard J ^c   Hesketh, Paul J ^d   Rittenberg, Cindy ^e   Elmer, Mary E ^f   Schmidt, Carrie ^f   Taylor, Arlene ^f   Carides, Alexandra D ^f   Evans, Judith K ^f   Horgan, Kevin J ^f  

^a Centry City Doctors Hospital   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c New York Lung Cancer Alliance   (United States)

^d ST ELIZABETH'S MEDICAL CENTER   (United States)

^e Rittenberg Oncology Consulting   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiemetic; Clinical trial; Neurokinin; Substance P

Indexed keywords

ANTIEMETIC AGENT; APREPITANT; CISPLATIN; DEXAMETHASONE; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HICCUP; HUMAN; INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT CANCER; RISK BENEFIT ANALYSIS; SOLID TUMOR; UROGENITAL TRACT CANCER;

ADMINISTRATION, ORAL; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; NEOPLASMS; ONDANSETRON; RECEPTORS, NEUROKININ-1; TREATMENT OUTCOME; VOMITING;

EID: 0037403701     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11320     Document Type: Article

References (26)

1. Hesketh PJ. Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists. Support Care Cancer. 1994;2:286-292.
2. de Boer-Dennert M, de Wit R, Schmitz PIM, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5-HT3 antagonists. Br J Cancer. 1997;76:1055-1061.
3. Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996;7:189-195.
4. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med. 1993;329:1790-1796.
5. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997;15:103-109.
6. Tavorath R, Hesketh PJ. Drug treatment of chemotherapyinduced delayed emesis. Drugs. 1996;52:639-648.
7. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999;17:2971-2994.
8. Watson JW, Gonsalves SF, Fossa AA, et al. The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol. 1995;115:84-94.
9. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol Rev. 1993;73:229-308.
10. Diemunsch P, Grélot L. Potential of substance P antagonists as antiemetics. Drugs. 2000;60:533-546.
11. Bountra C, Bunce K, Dale T, et al. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994 in ferrets. Eur J Pharmacol. 1993;249:R3-R4.
12. 1 receptor antagonist CP-99,994 attenuates cisplatin-induced emesis in the ferret. Eur J Pharmacol. 1993;250: R5-R6.
13. 1 receptor antagonist aprepitant (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology. 2000;39:652-663.
14. Cocquyt V, Van Belle S, Reinhardt RR, et al. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001;37:835-842.
15. Campos D, Pereira JR, Reinhardt RR, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001;19:1759-1767.
16. Van Belle S, Lichinitser M, Navari R, et al. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869: a randomized controlled trial. Cancer. 2002;94:3032-3041.
17. Navari R, Reinhardt R, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med. 1999;340:190-195.
18. Ortho-McNeil Pharmaceutical. Product information. ULTRAM®. U.S. package insert. Raritan, NJ: Ortho-McNeil Pharmaceutical, 2001.
19. Lo SK, Yip D, Leslie M, Harper P. 5-fluorouracil-induced erythema multiforme. Int J Clin Pract. 1999;53:219-221.
20. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600-1607.
21. Brodsky A, Aparici I, Argeri C, Goldenberg D. Stevens-Johnson syndrome, respiratory distress and acute renal failure due to synergic bleomycin-cisplatin toxicity. J Clin Pharmacol. 1989;29:821-823.
22. Olver I, Paska W, Depierre A, et al. A multicenter, doubleblind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol. 1996;7:945-952.
23. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954-963.
24. De La Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transplant Infect Dis. 2002;4:3-9.
25. DeMaria EJ, Reichman W, Kenney PR, Armitage JM, Gann DS. Septic complications of corticosteroid administration after central nervous system trauma. Ann Surg 1985;207:248-252.
26. Gerndt SJ, Rodriguez JL, Pawlik JW, et al. Consequences of high-dose steroid therapy for acute spinal cord injury. J Trauma Injury Infect Crit Care. 1997;42:279-284.